Studies of Alternations of c-MET in SCLC

SCLC 中 c-MET 变化的研究

• 批准号: 6925622
• 负责人: Patrick C Ma
• 金额: $ 13.11万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-22 至 2010-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6925622
• 关键词: RNA splicing; antineoplastics; biological signal transduction; cell line; cytoskeleton; gene mutation; molecular oncology; neoplasm /cancer genetics; neoplasm /cancer invasiveness; neoplastic growth; phosphatidylinositol 3 kinase; protein tyrosine kinase; protooncogene; small cell lung cancer; video microscopy

DESCRIPTION (provided by applicant): The proposed project will be performed under the mentorship of Dr. Ravi Salgia, who has great expertise in the tyrosine kinases, cytoskeleton, and invasion/metastasis in SCLC. My long term career goal is to become an independent clinician-scientist in translational cancer research with focus on targeted therapeutics. I have found that c-Met is expressed, functional and sometimes mutated in SCLC. I have novel immunohistochemistry finding of the activated phospho-Met localized preferentially at the tumor invasive front. In the recently completed c-Met mutational analysis in SCLC, I have identified novel alternatively spliced transcripts and somatic mutations of c-Met, particularly in the Sema domain and the juxtamembrane (JM) domain. The JM-mutations were found to alter c-Met signaling with increased tyrosine phosphorylation including the key focal adhesion protein paxillin. This was found correlating with enhanced tumorigenesis and cell motility/migration by the JM mutations. These results suggest a unique role of the JM-domain in c-Met signaling with dramatic effects in cytoskeletal functions. Preliminary studies with two available specific c-Met inhibitors (SU11274 and PHA665752) have shown promising inhibition of viability and motility of SCLC. I now aim to further determine the functional implications of the various c-Met mutations in SCLC, such as viability, survival/ apoptosis, and transformation. Effects of the c-Met mutations on the downstream PI3K/Akt signaling pathway would be determined with combinations of PI3K-kinase assay, IP/IB, and also PI3K inhibitors. Cell lines expressing wild-type or mutated Met would be established and utilized in functional analyses. Various biological assays, such as scattering, motility/migration, and invasion would be investigated. Utilizing phosphospecific antibodies against focal adhesion proteins, and time-lapse video-microscopy, studies would be focused on cytoskeletal functions. The role of various inhibitors of c-Met and its mutants in SCLC would be further defined aiming to translate into novel targeted-therapeutics.

项目描述（由申请人提供）：该项目将由Ravi Salgia博士指导，他在SCLC的酪氨酸激酶，细胞骨架和侵袭/转移方面具有丰富的专业知识。我的长期职业目标是成为一名独立的临床医生和科学家，专注于靶向治疗的转化癌症研究。我发现c-Met在SCLC中有表达，有功能，有时还会发生突变。我有新的免疫组织化学发现活化的磷酸met优先定位于肿瘤侵袭前部。在最近完成的SCLC c-Met突变分析中，我发现了新的可选剪接转录本和c-Met的体细胞突变，特别是在Sema结构域和近膜（JM）结构域。发现jm突变改变c-Met信号，增加酪氨酸磷酸化，包括关键的局灶粘附蛋白paxillin。这被发现与JM突变增强的肿瘤发生和细胞运动/迁移有关。这些结果表明，jm结构域在c-Met信号传导中具有独特的作用，对细胞骨架功能有显著影响。两种特异性c-Met抑制剂（SU11274和PHA665752）的初步研究显示有希望抑制SCLC的活力和运动。我现在的目标是进一步确定各种c-Met突变在SCLC中的功能意义，如生存能力、存活/凋亡和转化。c-Met突变对下游PI3K/Akt信号通路的影响将通过PI3K激酶测定、IP/IB和PI3K抑制剂的组合来确定。将建立表达野生型或突变Met的细胞系并用于功能分析。各种生物分析，如散射、运动/迁移和入侵将被调查。利用针对黏附蛋白的磷特异性抗体和延时视频显微镜，研究将集中在细胞骨架功能上。各种c-Met抑制剂及其突变体在SCLC中的作用将进一步确定，旨在转化为新的靶向治疗方法。